AMRN Share Price

Open 2.92 Change Price %
High 2.97 1 Day 0.00 0.00
Low 2.90 1 Week -0.08 -2.67
Close 2.92 1 Month -0.25 -7.89
Volume 1240917 1 Year 1.50 105.63
52 Week High 3.65
52 Week Low 1.24
AMRN Important Levels
Resistance 2 2.98
Resistance 1 2.96
Pivot 2.93
Support 1 2.88
Support 2 2.86
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
APRI 2.86 89.40%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
APRI 2.86 89.40%
AMCF 0.06 50.00%
LOCM 0.09 50.00%
SKBI 0.12 50.00%
UNXL 1.69 34.13%
LIFE 3.25 32.65%
CHCI 2.42 29.41%
GLBS 6.17 27.22%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

Amarin Corporation PLC (NASDAQ: AMRN)

AMRN Technical Analysis 1.5
As on 18th Jan 2017 AMRN Share Price closed @ 2.92 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.48 & Sell for SHORT-TERM with Stoploss of 3.15 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMRN Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
AMRN Other Details
Segment EQ
Market Capital 1595353216.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.amarincorp.com
AMRN Address
AMRN
2 Pembroke House
Upper Pembroke Street 28-32
Dublin, 2
Ireland
Phone: 353 1 669 9020
AMRN Latest News
Interactive Technical Analysis Chart Amarin Corporation PLC ( AMRN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amarin Corporation PLC
AMRN Business Profile
Amarin Corporation plc (Amarin), incorporated on March 1, 1989, is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial). The MARINE trial is conducted with omega-3 fatty acids in treating patients with very high triglycerides, is a Phase-III, multi-center, placebo-controlled, randomized, double-blind, 12-week study. Patients enrolled in the MARINE trial were given the option to be treated with AMR101 for a period of up to 40-weeks after their last dose in the pivotal trial. The ANCHOR trial is a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study in patients with high triglycerides who were on optimized statin therapy. In April 2011, it reported top-line results from the ANCHOR trial. Prior to commencing the MARINE and ANCHOR trials, it conducted a pre-clinical program for AMR101, including toxicology and pharmacology studies. In addition to the MARINE and ANCHOR trials, it completed a 28-day pharmacokinetic study. It is also focusing development of other compounds based on its internal lipid science expertise.